{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-046815","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.160598+00:00","generated_at":"2026-06-19T01:39:53.909285+00:00","sec_items":["1.01","5.02","5.03","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MEI Pharma to merge with Infinity Pharmaceuticals in stock-for-stock deal","bullets":["MEI Pharma to acquire Infinity via merger; Infinity stockholders receive 1.0449 MEI shares per share.","Combined company ownership: ~58% MEI stockholders, ~42% Infinity stockholders.","Closing expected mid-2023; termination fees of $4M (MEI) or $2.9M (Infinity) under certain conditions.","CEO Daniel Gold to resign; David Urso appointed CEO. Infinity's CMO and CSO to join combined company.","Board changes: three MEI directors resign; Norman Selby, Adelene Perkins, Richard Gaynor appointed."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-046815","json":"https://secwatch.observer/filing/0001193125-23-046815.json","markdown":"https://secwatch.observer/filing/0001193125-23-046815.md","text":"https://secwatch.observer/filing/0001193125-23-046815.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523046815/0001193125-23-046815-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523046815/d428092d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T01:39:53.909285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1ec5b571b3","claim":"Frederick W. Driscoll departed as Director at Lite Strategy, Inc..","evidence_excerpt":"Tamar D. Howson, Nicholas R. Glover and Frederick W. Driscoll will resign from the Board of Directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523046815/0001193125-23-046815-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will resign from the Board of Directors"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"45fc3ceb27","claim":"David M. Urso changed role as Chief Executive Officer at Lite Strategy, Inc..","evidence_excerpt":"David M. Urso will become Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523046815/0001193125-23-046815-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will become Chief Executive Officer"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"49eff6aeec","claim":"Nicholas R. Glover departed as Director at Lite Strategy, Inc..","evidence_excerpt":"Tamar D. Howson, Nicholas R. Glover and Frederick W. Driscoll will resign from the Board of Directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523046815/0001193125-23-046815-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will resign from the Board of Directors"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"58afecd5df","claim":"Daniel Gold departed as Director at Lite Strategy, Inc..","evidence_excerpt":"Daniel Gold, Ph.D. will resign as Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523046815/0001193125-23-046815-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will resign as Chief Executive Officer and continue on Board"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"89138aaa11","claim":"Tamar D. Howson departed as Director at Lite Strategy, Inc..","evidence_excerpt":"Tamar D. Howson, Nicholas R. Glover and Frederick W. Driscoll will resign from the Board of Directors of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523046815/0001193125-23-046815-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will resign from the Board of Directors"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"ee871ce6bd","claim":"Stéphane Peluso was appointed as Chief Scientific Officer at Lite Strategy, Inc..","evidence_excerpt":"Stéphane Peluso will become Chief Scientific Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523046815/0001193125-23-046815-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will become Chief Scientific Officer"},{"label":"Role","value":"Chief Scientific Officer"}],"fact_type":"executive_change"},{"claim_id":"f773b1fca9","claim":"Robert Ilaria Jr. was appointed as Chief Medical Officer at Lite Strategy, Inc..","evidence_excerpt":"Robert Ilaria Jr. will become Chief Medical Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523046815/0001193125-23-046815-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will become Chief Medical Officer"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"bd2a396d0f0b8dcea543544ad9dd509f4fe864dc","claim":"Lite Strategy, Inc.: The Company adopted Fifth Amended and Restated Bylaws to address Universal Proxy Rules and update forum selection provisions (effective 2023-02-22).","evidence_excerpt":"On February 22, 2023, in connection with the effectiveness of new SEC rules regarding universal proxy cards and a periodic review of the bylaws of Company, the Company’s board of directors (the “Board”) approved and adopted the Company’s fifth amended and restated bylaws (the “Fifth Amended and Restated Bylaws”), which became immediately effective.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523046815/0001193125-23-046815-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2023-02-22"}],"fact_type":"governance_change"},{"claim_id":"65420469f9e841c413cfde6e34e0cf50623f3a1c","claim":"Lite Strategy, Inc. entered into Agreement and Plan of Merger with Infinity Pharmaceuticals, Inc. (effective 2023-02-22).","evidence_excerpt":"On February 22, 2023, MEI Pharma, Inc, a Delaware corporation (the “Company”), Infinity Pharmaceuticals, Inc., a Delaware corporation (“Infinity”), and Meadow Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of the Company (“Merger Sub” each of the Company, Merger Sub and Infinity are each sometimes referred to herein as a “Party” and collectively as the “Parties”) entered into an Agreement and Plan of Merger (the “Merger Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000119312523046815/0001193125-23-046815-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Infinity Pharmaceuticals, Inc."},{"label":"Effective","value":"2023-02-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}